Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
Valion Bio’s subsidiary Velocity Bioworks secured an exclusive commercial license to LarmorBio’s BioScan-NMR platform, a next-generation NMR system for rapid cell phenotyping. The deal includes a strategic reference site arrangement, with the first commercial installation targeted for July 2026 at Valion’s San Antonio facility.
Key figures
- Installation target
- July 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.